A trial in phase 2 metastatic prostate cancer shows that some patients likely to benefit from ipilimumab treatment, even with low number of tumor mutations.
Victoria Forster, PhD
Victoria Forster is a postdoctoral research scientist and freelance science writer. Her research interests include; DNA repair deficiencies, pediatric cancers, stem cell and organoid models for cancer development and cancer treatment-related side effects. She is also a 25-year survivor of childhood leukemia and an advocate for childhood cancer awareness. She has bylines in several outlets including The Times, The Guardian, Forbes, and Cancer Therapy Advisor.